369 related articles for article (PubMed ID: 17112769)
1. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
Hasegawa Y; Goto M; Hanai N; Ijichi K; Adachi M; Terada A; Hyodo I; Ogawa T; Furukawa T
Oral Oncol; 2007 Sep; 43(8):749-56. PubMed ID: 17112769
[TBL] [Abstract][Full Text] [Related]
2. Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma.
Hasegawa Y; Goto M; Hanai N; Ijichi K; Terada A; Hyodo I; Ogawa T; Fukushima M
Oncology; 2007; 73(1-2):104-11. PubMed ID: 18337622
[TBL] [Abstract][Full Text] [Related]
3. Clinical applications of the histoculture drug response assay.
Furukawa T; Kubota T; Hoffman RM
Clin Cancer Res; 1995 Mar; 1(3):305-11. PubMed ID: 9815986
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Chang PM; Chen PM; Chu PY; Wang LW; Tai SK; Tsai TL; Huang JL; Wang YF; Chang SY; Yang MH
Cancer Chemother Pharmacol; 2008 Dec; 63(1):9-17. PubMed ID: 18343925
[TBL] [Abstract][Full Text] [Related]
6. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
[TBL] [Abstract][Full Text] [Related]
7. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
Choi YJ; Chung JS; Shin HJ; Cho GJ; Wang SG; Lee BJ; Cho BM; Joo YD; Sohn CH
J Laryngol Otol; 2008 Aug; 122(8):848-53. PubMed ID: 18047761
[TBL] [Abstract][Full Text] [Related]
10. [Attempts to improve organ preservation in patients with squamous cell carcinoma of the head and neck].
Taguchi T; Tsukuda M
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2030-4. PubMed ID: 16352924
[TBL] [Abstract][Full Text] [Related]
11. Red blood cell glutathione levels before and during treatment with neoadjuvant chemotherapy cisplatin/5-fluorouracil in patients with head and neck squamous cell carcinoma.
Massaad-Massade L; Domenge C; Rongeat S; Hassoun L; Legros MH; Ropers J; Janot F; Parise O; Gouyette A
Anticancer Res; 1998; 18(1A):283-8. PubMed ID: 9568091
[TBL] [Abstract][Full Text] [Related]
12. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
[TBL] [Abstract][Full Text] [Related]
13. Results and failures with or without cisplatin containing induction chemotherapy in the treatment of squamous cell carcinoma of the head and neck.
Olasz L; Németh A; Nyárády Z; Tornóczky T; Királyfalvi L
Cancer Detect Prev; 2004; 28(1):65-71. PubMed ID: 15041080
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers.
Koiwai K; Shikama N; Sasaki S; Shinoda A; Kadoya M
Jpn J Clin Oncol; 2009 Jul; 39(7):413-7. PubMed ID: 19383615
[TBL] [Abstract][Full Text] [Related]
15. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
[TBL] [Abstract][Full Text] [Related]
16. [Induction chemotherapy based on histoculture drug response assay for a patient with advanced thymic cancer--a case report].
Tanino H; Miyoshi S; Furukawa T; Bessho T; Maebeya S; Suzuma T; Hirai I; Arimoto J; Harada N; Hoso T; Naito Y
Gan To Kagaku Ryoho; 1997 May; 24(7):861-4. PubMed ID: 9170526
[TBL] [Abstract][Full Text] [Related]
17. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
[TBL] [Abstract][Full Text] [Related]
18. The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck.
Uygun K; Bilici A; Karagol H; Caloglu M; Cicin I; Aksu G; Fayda M; Uzunoglu S
Cancer Chemother Pharmacol; 2009 Aug; 64(3):601-5. PubMed ID: 19123002
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
O'Meara AT; Sevin BU
Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
[TBL] [Abstract][Full Text] [Related]
20. [Combination chemotherapy with S-1 and carboplatin for head and neck cancers].
Watanabe A; Taniguchi M; Tsujie H
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():155-9. PubMed ID: 16897993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
